HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight.

AuthorsT Schöndorf, T Forst, C Hohberg, S Pahler, C Link, W Roth, A Pfützner, G Lübben, C Link, A Pfützner
JournalDiabetes, obesity & metabolism (Diabetes Obes Metab) Vol. 9 Issue 1 Pg. 132-3 (Jan 2007) ISSN: 1462-8902 [Print] England
PMID17199730 (Publication Type: Clinical Trial, Letter, Multicenter Study)
Chemical References
  • Hypoglycemic Agents
  • Thiazolidinediones
  • Pioglitazone
Topics
  • Aged
  • Body Weight (drug effects)
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Female
  • Humans
  • Hypertension (drug therapy)
  • Hypoglycemic Agents (therapeutic use)
  • Male
  • Metabolic Syndrome (drug therapy)
  • Middle Aged
  • Pioglitazone
  • Thiazolidinediones (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: